Sort by
Refine Your Search
-
research on characterizing non-coding regulatory elements in humans and understanding how these elements change across different conditions. The project will involve developing new modeling approaches
-
collaborative and interdisciplinary research environment. Preferred Qualifications Experience with computational structural biology, molecular modeling, or AI-assisted drug discovery is desirable but not required
-
(TurboID), phosphoproteomics, and mouse models (including bGHTg acromegaly mice and breast cancer xenografts), we aim to uncover fundamental mechanisms of IGF1R antagonism and develop peptide‑based
-
Qualifications Minimum Education and Experience PhD in Biomedical Engineering, Electrical Engineering, Materials Science, or a closely related field. Proven track record of research in flexible electronics
-
model and behavior, 2) animal survival and non-survival surgeries 3) confocal/two photon imaging, 4) synaptic biology or physiology. Candidates in ABD (all but degree) status will also be considered
-
hope for cancer patients and their families and play a critical role in strengthening the fabric of our communities by gaining and protecting their trust and providing access to the outstanding oncology
-
, receptor signaling assays, in vivo mouse models, and molecular or immunological techniques under the PI’s guidance. Meets with the principal investigator to establish goals and objectives for ongoing
-
Required Knowledge, Skills, and Abilities Excellent quantitative analytical skills, particularly in longitudinal modeling, administrative data analyses, and causal inference methods. Understanding of HIPAA
-
) primary neuronal cell culture 2) live cell imaging, confocal/two photon imaging 3) synaptic biology or physiology, 4) animal model, behavior, pathology. Candidates in ABD (all but degree) status will also
-
hope for cancer patients and their families and play a critical role in strengthening the fabric of our communities by gaining and protecting their trust and providing access to the outstanding oncology